A prospective pilot study of kidney-specific biomarkers to detect acute kidney injury after cytoreduction and hyperthermic intraperitoneal chemotherapy
2024

Kidney Biomarkers and Acute Kidney Injury After Chemotherapy

Sample size: 75 publication 10 minutes Evidence: moderate

Author Information

Author(s): Chen Chao-Yu, Wang Ting-Yao, Chang Hung-Yu, Chen Min-Chi, Yang Lan-Yan

Primary Institution: Chang Gung Memorial Hospital, Chiayi, Taiwan

Hypothesis

Can kidney-specific biomarkers accurately predict acute kidney injury after cytoreduction and hyperthermic intraperitoneal chemotherapy?

Conclusion

The study found that variations in kidney-specific biomarkers may help predict acute kidney injury, but absolute measurements alone are not sufficient.

Supporting Evidence

  • 5 out of 75 patients developed acute kidney injury during the study.
  • Significant differences in biomarker levels were observed on specific days post-surgery.
  • The study was conducted over a period from January 2018 to December 2020.

Takeaway

Doctors are trying to find better ways to tell if kidneys are hurt after surgery and chemotherapy, and some special tests might help.

Methodology

This was a prospective observational study where urine and serum samples were collected from patients undergoing CRS/HIPEC to measure kidney-specific biomarkers.

Potential Biases

Potential bias due to the observational nature of the study and the lack of blinding.

Limitations

The study had a small sample size and a low number of acute kidney injury cases, which may limit the generalizability of the findings.

Participant Demographics

Median age was 60 years, with a mix of cancer types including gastric, ovarian, and colorectal cancers.

Statistical Information

P-Value

0.025

Confidence Interval

95% CI, 0.73–0.76

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.2478/abm-2024-0034

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication